Viridax™ is
Dedicated to the Development of Bacteriophage Therapeutic Products for the
Treatment of Respiratory, Systemic and Topical Infections Incited by
Staphylococcus aureus and other
Staphylococcal species
An infectious disease crisis of global proportions is
threatening our hard-won gains in health and life expectancy. Infectious
diseases are now the world's biggest killer of children and young adults. Many
diseases once thought unrelated to infectious diseases, especially cancers, are
now known to result from chronic infections. No country is safe from the threat
of infectious diseases.
This is happening at a time when the arsenal
of drugs available to treat infectious diseases is being depleted because of the
increasing resistance of microbes to antimicrobial drugs. The scale and
complexity of the infectious disease crisis is great. If we fail to bring
forward new antimicrobial agents now, increased drug resistance and the
emergence of new infectious agents threaten to make the control of infectious
diseases both scientifically and economically unlikely in the future.
| 
